SAN FRANCISCO, Dec. 11, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and Cynvenio Biosystems, Inc., a cancer diagnostics company, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by Cynvenio. The combined molecular testing and medical informatics solution will enable a more personalized approach to disease management by physicians who incorporate the results of molecular diagnostic testing into patient treatment planning.
Under the current agreement, multiple CollabRx products, including the Genetic Variant Annotation (GVA) Service™ will be paired with tumor mutation profiling conducted by Cynvenio. Reports developed using the GVA Service will be offered with the Cynvenio ClearID Breast Cancer blood test, for monitoring breast cancer survivors at high risk of recurrence. ClearID identifies circulating tumor cells carrying cancer-associated mutations with next generation sequencing. Cynvenio will combine the results of these tests with clinically actionable and dynamically updated data provided by the CollabRx GVA Service. The GVA database includes information on the clinical impact of specific genetic profiles and associated therapeutic strategies such as drugs and investigational therapies being tested in clinical trials. This knowledge is further contextualized in collaboration with CollabRx's large and growing network of over 75 leading clinical practitioners in the U.S. and Europe.
"A contextualized interpretation of sequencing results is required to make the results of genomic tests actionable for physicians providing highly personalized cancer treatments to their patients," said André de Fusco, CEO of Cynvenio. "CollabRx has developed a scalable process and software platform to provide key elements of the reporting solution that Cynvenio provides to aid physicians in the clinical interpretation of tumor-specific molecular profiles. We are pleased to be able to include GVA with our molecular testing services."
"Cynvenio has introduced an innovative, blood test to help monitor for disease in breast cancer survivors at high risk for recurrence," said Thomas Mika, Chairman, President & CEO of CollabRx. "Their approach of combining the detection of circulating tumor cells with genomic analysis is important for the early detection of cancer, choice of therapy, and ultimately to achieve the best possible clinical outcomes for breast cancer patients. We chose to extend CollabRx expertise and services to 'liquid biopsy' for the first time with Cynvenio because they are at the forefront of the sector with a strong focus on advancing personalized medicine in cancer."
The partnership with Cynvenio demonstrates CollabRx's accelerating pace of business and channel development in 2013. This new milestone attests to the growing adoption of CollabRx technology and interpretive analytics in top-tier laboratories worldwide as a standard aspect of test reporting for clinical genetic sequencing in cancer and other diseases.
The companion announcement from Cynvenio is available on: http://www.cynvenio.com.
About CollabRx
CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
About Cynvenio
Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in the bloodstream. This expertise has resulted in two distinct product offerings: ClearID Breast Cancer monitoring program and LiquidBiopsy®. ClearID Breast Cancer, designed for use by patients and their physicians, is a cancer detection and monitoring program that assesses 50 oncogenes for more than 4,500 genetic mutations using next-generation sequencing. This test and real-time molecular analysis provide actionable information that can inform treatment considerations and help improve treatment outcomes. LiquidBiopsy is designed for industry and academic researchers to identify the presence of tumor-cell genetic mutations in whole blood. Founded in 2008, Cynvenio is headquartered in Westlake Village, Calif. (Los Angeles). For more information visit http://www.cynvenio.com.
LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.
CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx's anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx's plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.